Extended Data Fig. 9: NRF2 activation licences NRASG12V-induced HCC development.
From: FBP1 controls liver cancer evolution from senescent MASH hepatocytes
a-d, IHC of FFPE liver sections from Nrf2Tg/Tg and Nrf2Act-Hep livers 1, 4, 12 and 16 weeks after NRASG12 HTVI (n = 4-5 BR) (a, c). Scale bars, 50 μm. Relative staining intensities per HMF determined by Image J (b, d). e, Tumour numbers and volumes in Nrf2Tg/Tg and Nrf2Act-Hep mice 12 and 16 weeks after HTVI of NRASG12V (n = 4-5 BR). Data in b, d and e are mean ± SEM. Statistical significance determined by two-sided unpaired t-test or Mann–Whitney U test (b, d) and Kruskal–Wallis test with Dunn post-hoc tests (e) based on data normality distribution. **P < 0.01, ***P < 0.001, ****P < 0.0001.
